|
受注：045-509-1970 |
技術サポート：tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
化学情報
|
Synonyms | NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP | Storage (From the date of receipt) |
2 years 4°C(in the dark) powder |
| 化学式 | Cl2H6N2Pt |
|||
| 分子量 | 300.05 | CAS No. | 15663-27-1 | |
| Solubility (25°C)* | 体外 | DMF | 7.5 mg/mL (24.99 mM) | |
| Water | 2.5 mg/mL warmed with 50ºC water bath (8.33 mM) | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
||||
溶剤液（一定の濃度）を調合する
生物活性
| 製品説明 | シスプラチン (Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP)) は無機白金錯体であり、腫瘍細胞中において DNA 付加物を形成することにより DNA 合成を阻害する能力を有します。シスプラチンはフェロトーシス (ferroptosis) を活性化し、オートファジー (autophagy) を誘導します。溶液は都度調製してください。Solutions are unstable and should be fresh-prepared.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation. |
|---|---|
| in vitro | Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, which culminates in the activation of apoptosis. [1] This compound (30 μM) treated for 6 h induces an apparent activation of Erk in HeLa cells, which is sustained over the following 14 h period. It also shows an effective antineoplastic activity by inducing tumor cells death[2]. It displays ability to cause renal proximal tubular cell (RPTC) apoptosis, causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively. [4] This chemical (800 μM) causes typical features of necrosis of RPTC after treatment for 4 hr. [5] |
| in vivo | Cisplatin has been demonstrated to be efficient in regression tumor growth in a wide variety of animal tumors models, including head and neck cancer xenografts, cervical squamous carcinoma xenografts, testicular carcinoma xenografts, ovarian cancer xenografts, breast carcinoma xenografts, colonic carcinoma, heterotransplanted hepatoblastoma, and so on. This compound (5 mg/kg) given weekly i.v. at the day 1 and 7 induces a tumor growth inhibition (GI) of 77.5% and 85.1% of the serous xenografts Ov.Ri(C) and OVCAR-3, respectively. [6] |
| 特徴 | One of the most widely used and most potent chemotherapeutic agents. This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[7] |
プロトコル(参考用のみ)
| 細胞アッセイ | 細胞株 | Leukemia L1210/0 cells |
|---|---|---|
| 濃度 | 7 μg/mL | |
| 反応時間 | 2 hours | |
| 実験の流れ | L1210/0 cells are maintained in an exponential suspension culture at 37 ℃ in a humidified atmosphere of 5% CO2 in McCoy's medium 5a (modified), supplemented with 15% calfserum, and Fungizone. L1210/0 cells are incubated in Cisplatin (7 μg/mL) for 2 hr at 37 ℃. To measure growth inhibition, the cells are centrifuged, washed once, resuspended in fresh medium at 30 × 103 to 50 × 103 cells/mL, and incubated for 3 days. Cell numbers are determined on a Coulter Counter. An aliquot of cells is diluted with an equal volume of 0.4% trypan blue. Viability is recorded as the percentage of cells that has excluded trypan blue. Cells incubated with this compound as above are also diluted into 0.1% agar and allowed to grow for 2 weeks when colonies are counted. |
|
| 動物実験 | 動物モデル | Female NMRI/Cpb (nuinu) mice |
| 投薬量 | 5 mg/kg | |
| 投与方法 | i.v. |
参考
|
カスタマーフィードバック
-
Data from [Cancer Res, 2014, 74(1), 298-308]
-
Data from [PLoS One, 2013, 8(1), e54595]
-
, 2013, Dr. Edita Aksamitiene from Thomas Jefferson University
Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：
| A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer [ Cell, 2025, S0092-8674(25)00291-0] | PubMed: 40147443 |
| Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models [ Cancer Cell, 2025, S1535-6108(25)00223-5] | PubMed: 40513578 |
| A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy [ Cell Stem Cell, 2025, S1934-5909(25)00265-6] | PubMed: 40812300 |
| Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma [ Cancer Commun (Lond), 2025, 10.1002/cac2.70036] | PubMed: 40443016 |
| SUMO4 promotes SUMO deconjugation required for DNA double-strand-break repair [ Mol Cell, 2025, 85(5):877-893.e9] | PubMed: 40054443 |
| Organoid morphology-guided classification for oral cancer reveals prognosis [ Cell Rep Med, 2025, 6(5):102129] | PubMed: 40359934 |
| A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer [ Cell Rep Med, 2025, 6(7):102233] | PubMed: 40633540 |
| TBK1 is a signaling hub in coordinating stress-adaptive mechanisms in head and neck cancer progression [ Autophagy, 2025, 1-23.] | PubMed: 40114316 |
| A novel pathway for stemness propagation and chemoresistance in non-small cell lung cancer via phosphorylated PKM2-loaded small extracellular vesicles [ Theranostics, 2025, 15(8):3439-3461] | PubMed: 40093893 |
| Identification of microprotein-coding intronic polyadenylation isoforms and function in genotoxic anticancer drug response [ Genome Biol, 2025, 26(1):366] | PubMed: 41131620 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。